Zai Lab Limited — FY2019 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2019. Although the request references 2019 Q4, this filing reports annual results and does not provide standalone fourth-quarter financials. Amounts below are in U.S. dollars unless stated otherwise.
Business context
Zai Lab is a commercial-stage biopharmaceutical company focused on licensing, developing and commercializing medicines and medical devices, primarily for oncology, infectious and autoimmune diseases. In 2019, ZEJULA and Optune generated product sales. ZEJULA received China approval in December 2019 and launched there in January 2020; it was also commercialized in Hong Kong and Macau. Optune was commercialized in Hong Kong.
Key financial metrics
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | $12.985 million | $0.129 million |
| Cost of sales | $3.749 million | $0.043 million |
| Gross profit / margin | $9.236 million / approximately 71% | $0.086 million / approximately 67% |
| Research and development expense | $142.221 million | $120.278 million |
| Selling, general and administrative expense | $70.211 million | $21.576 million |
| Operating loss | $203.196 million | $141.768 million |
| Net loss | $195.071 million | $139.075 million |
| Basic and diluted loss per share | $3.03 | $2.64 |
| Net cash used in operating activities | $191.011 million | $97.538 million |
Gross margins are approximate calculations from reported revenue and cost of sales; the filing does not present them as a separate line item. The company reported no income tax expense. Interest income was $8.232 million, versus $3.261 million in 2018.
At year-end, cash and cash equivalents were $75.932 million, restricted cash was $0.510 million, and short-term investments were $200.000 million. Total assets were $355.153 million; shareholders’ equity was $294.660 million; total liabilities were $60.493 million. Short-term borrowings were $6.450 million. Operating lease liabilities totaled $15.328 million, including current and non-current portions. Management said available cash and short-term investments were expected to fund operating and capital requirements for at least 12 months, subject to assumptions that may prove incorrect.
Material changes versus FY2018
- Revenue rose to $12.985 million from $0.129 million as product commercialization began to scale; the filing does not disclose product-level revenue.
- Net loss increased by $55.996 million. R&D expense rose $21.943 million, principally reflecting higher personnel costs and clinical-development spending; licensing fees remained substantial at $58.682 million.
- SG&A expense increased $48.635 million, largely because of commercial and administrative hiring and selling, rental and travel costs associated with commercialization.
- Operating cash use nearly doubled. Financing activities provided $219.302 million, mainly from the 2019 follow-on offering; investing cash use fell to $14.892 million, primarily reflecting maturities of short-term investments.
Outlook, risks and notable items
- Outlook: No numerical revenue or earnings guidance is provided. Management expects losses and expenses to continue, with spending driven by commercialization, clinical development, manufacturing and organizational growth. A January 2020 ADS offering generated $280.568 million in net proceeds, a subsequent event not included in 2019 year-end cash.
- Commercial and pipeline risks: Profitability depends on ZEJULA and Optune adoption, pricing and reimbursement, and successful development and approval of pipeline assets. Products and candidates face competition, regulatory uncertainty, safety risks, supply dependence and substantial third-party license obligations.
- COVID-19: The filing reports some patient-access and clinical-trial enrollment delays in China, with minimal disruption to commercialization and planned trials as of the filing’s April 2020 discussion. Further outbreaks could disrupt operations, enrollment or supply.
- Customer concentration: Approximately 80% of 2019 revenue came from one Hong Kong customer; all year-end accounts receivable was from the Hong Kong distributor.
- Audit and controls: The auditor issued an unqualified opinion on the financial statements and internal control over financial reporting. R&D expense cut-off was identified as a critical audit matter because accruals for CRO/CMO services require judgments about project progress and milestones; this was not an adverse audit opinion.
- Other: The company reported no material legal proceedings and no dividends paid or currently planned. Management identified no significant changes after the audited financial statements, apart from disclosed subsequent events.
Important facts for investors to verify
- Reconcile the filing’s conflicting year-end ordinary-share counts: the cover page reports 68,375,511 issued and outstanding shares, while the audited balance sheet reports 68,237,247.
- Review product revenue, sales growth and gross margin by product and geography; the filing does not provide a clear product-level revenue breakdown.
- Assess the cash-burn trajectory against the stated runway, including the impact of the January 2020 offering and planned development and commercialization spending.
- Check the status, costs and potential obligations of major licensing agreements, clinical programs and regulatory applications.
- Monitor revenue concentration, reimbursement and pricing developments, and COVID-related effects on patients, trials and supply chains.